Clinical Trial Detail

NCT ID NCT03581487
Title Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Selumetinib + Tremelimumab

Age Groups: adult senior

No variant requirements are available.